Expert Perspectives in Multiple Myeloma

Benefits of Early CAR T-Cell Therapy in Multiple Myeloma

Stephanie Gregory, MS, FNP-C, BMTCN, and Jacob Bartlett, PA-C, from Northside Hospital discuss the clinical advantages of utilizing CAR T-cell therapy in earlier lines of treatment for multiple myeloma. They emphasize that early intervention, facilitated by prompt referrals to specialized centers, can lead to more durable remissions and a better quality of life for patients by utilizing their T-cells before they become exhausted by multiple prior treatments.

Samantha Shenoy, MS, MSN, ACNP-BC: Long-term Follow-up Results from CARTITUDE-1 Study and How APPs Can Educate Patients About the Data Effectively

Samantha Shenoy, MS, MSN, ACNP-BC, provides findings on the long-term follow-up data from CARTITUDE-1 for ciltacabtagene autoleucel. She stressed the importance of this being a one-and-done therapy where patients can remain in remission for years and return to their regular lives, and how APPs can educate their patients who are eligible for this treatment.

Mary Steinbach, DNP, APRN, and Eliza Parkin, NP: Addressing the Safety Profile of Multiple Myeloma Therapy

Mary Steinbach, DNP, APRN, and Eliza Parkin, NP, discuss the importance of educating patients about the safety profile of multiple myeloma treatment and how to guide patients through adverse events.

Mary Steinbach, DNP, APRN, and Eliza Parkin, NP: Instilling Confidence in NPs when Communicating with their Patients about Multiple Myeloma Treatment

Mary Steinbach, DNP, APRN, and Eliza Parkin, NP, discuss the importance of having confidence when providing care for patients with multiple myeloma. They provide tips on how to increase confidence and knowledge regarding multiple myeloma treatment.